Skip to main content

Table 1 Medicine and service codes used to identify endocrine therapies, comorbidity and cancer recurrence, by data source

From: Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?

Description

Name and item code

Pharmaceutical benefits scheme

Endocrine therapies subsidised for early breast cancer

Anastrozole (8179L); exemestane (8506Q); letrozole (8245Y); tamoxifen (2109B, 2110C).

Anxiety treatments

Alprazolam (2130D, 2131E, 2132F, 8118G); diazepam (3161J, 3162K); oxazepam 3132W 3133X).

Depression treatments

Amitriptyline (2417F, 2418G, 2429W); citalopram (8220P, 8702B, 8703C); dothiepin (1357K, 1358L); doxepin (1011F, 1012G, 1013H); escitalopram (8700X, 8701Y, 9433L, 9711D, 9727Y, 9728B); fluoxetine (1434L, 8270G); fluvoxamine (8174F); imipramine (2421K); mianserin (1627P, 1628Q); moclobemide (1900B, 8003F); mirtazapine (8513C, 8855C, 8856D, 8857E, 8883M); nortriptyline (2522R, 2323T); paroxetine (2242B); reboxetine (8583R); sertraline (2236Q, 2237R, 8836C, 8837D); venlafaxinea (8068P, 8301X, 8302Y, 8868R).

Hot flash treatments

Clonidine (3141H, 3145M).

Musculoskeletal pain treatments

Celecoxib (8439E, 8440F), diclofenac (1299J, 1300K, 1332D), ibuprofen (3190X, 3192B, 3198H, 5121M, 5124Q), indomethacin (2454E, 2757D); ketoprofen (1588N, 1590Q); meloxicam (8561N, 8562P, 8887R, 8888T); naproxen (1614Y, 1615B, 1659H, 1674D, 1795L); piroxicam (1895R, 1896T, 1897W, 1898X); rofecoxib (8471W, 8472X); sulindac (2047R, 2048T); tiaprofenic acid (2103Q).

Osteoporosis treatments

Alendronate (8102K, 8511Y, 9012H, 9183H, 9351E); etidronate (8056B); risedronate (8481J, 8621R, 8899J, 9147K, 9391G); strontium (3036T); zoledronate (9288W).

Vaginal atrophy treatment

Oestriol (1771F, 1776L, 1781R).

Medicines for advanced breast cancerb

Capecitabine (8362D, 8631C); lapatinib (9148L); medroxyprogesterone (2728N); megestrol (2734X), toremifene (8216K); vinorelbine (8280T, 8281W, 9009E, 9010F).

Medicare benefits schedule

Chemotherapy

13915, 13918, 13921, 13924, 13927, 13930 13933, 13936.

Radiotherapy

15000-15012, 15100-15115, 15211-15217, 15219-15232, 15234-15247, 15249-15262, 15264-15272, 15303-15337, 15339-15357, 15339-15357.

Admitted patient data collection

Services for cancer recurrence

Chemotherapy (13915, 13918, 13921, 13924, 13927, 13930 13933, 13936); lumpectomy (31500, 31503, 31506, 31509, 31512); mastectomy (31518, 31524); oophorectomy (35638, 35673, 35712, 35716, 35717, 35753, 35754).

  1. aVenlafaxine subsidy is restricted to use for major depressive disorders but some off-label or dual use may occur for hot flashes.
  2. bThese therapies are not subsidised for the treatment of early breast cancer.